Low‐dose colchicine vs NSAIDs
Withdrawals due to adverse events · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
11 questions · 11 findings · 7 reviews · Musculoskeletal
No studies found 3 · 27.3%GRADE not reported 2 · 18.2%Very low 2 · 18.2%Low 3 · 27.3%Moderate 1 · 9.1%High 0 · 0%
Low‐dose colchicine vs placebo
Withdrawals due to adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 133 participantsGRADE not reported
Any cold therapy vs no cold therapy following total knee replacement
Withdrawals due to adverse events · people undergoing total knee replacement
It is very uncertain whether any cold therapy changes withdrawals due to adverse events compared with no cold therapy following total knee replacement (very low certainty).
1 finding from 1 review
- RR 2.71 [0.42, 17.38]19 studies · 1347 participantsVery low
Anti‐TNF discontinuation vs anti‐TNF continuation
Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF discontinuation showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (moderate certainty).
1 finding from 1 review
- Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes onlyRR 1.46 [0.75, 2.84]4 studies · 1116 participantsModerate
Anti‐TNF dose reduction vs anti‐TNF continuation
Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF dose reduction showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
- Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes onlyRR 1.07 [0.51, 2.24]3 studies · 937 participantsLow
Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation
Withdrawals due to adverse events not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
The review found no eligible studies for this question.
1 finding from 1 review
- Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intermittent/cyclic etidronate 400 mg/day vs placebo
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes onlyRR 1.41 [0.81, 2.47]Studies not reportedLow
Risedronate 5 mg/day vs placebo
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes onlyRR 0.67 [0.38, 1.18]Studies not reportedLow
High‐dose vs low‐dose colchicine
Withdrawals due to adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 126 participantsGRADE not reported
Autologous blood or PRP vs placebo at 3 months' follow‐up
Withdrawals due to adverse events · lateral elbow pain
It is very uncertain whether autologous blood or PRP changes withdrawal due to adverse events  compared with placebo at 3 months' follow‐up (very low certainty).
1 finding from 1 review
- Autologous blood and platelet‐rich plasma injection therapy for lateral elbow pain 2021 · Cochrane Headline outcomes onlyRR 0.32 [0.03, 2.92]1 study · 80 participantsVery low
Intervention not reported
Severe adverse events or withdrawals (due to adverse events) ‐ not reported · People with hip or knee osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
- High‐intensity versus low‐intensity physical activity or exercise in people with hip or knee osteoarthritis 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found